EUVIMEDEUVIMED entdecken
Crossref

TRPC6 suppresses liver fibrosis by inhibiting hepatic stellate cell activation via CaMK4‐CREB pathway

Shan Jiang, Yujing Wang, Younan Ren, Qinglian Tang, Chu Xue, Zhi Wang, Qi Zhang, Yixin Hu, Hongbo Wang, Fang Zhao, Michael X Zhu iD, Zhengyu Cao iD

British Journal of Pharmacology · 2025-10 · 182 (20) · 5004-5022

DOI: 10.1111/bph.17431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 29.01.2025. Verfasst von Shan Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Research, School of Traditional …. Hauptthemen laut MEDLINE: Liver Cirrhosis, TRPC6 Cation Channel, Calcium-Calmodulin-Dependent Protein Kinase Type 4, Cyclic AMP Response Element-Binding Protein. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: National Natural Science Foundation of China, 'Double First-Class' University Project, Taishan Scholar Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Genetic ablation or inhibition of the cation channel TRPC6 is protective against renal, cardiac and intestinal fibrosis. However, TRPC6 expression is decreased in patients with liver diseases. Here, we explored the role of TRPC6 in liver fibrosis and the underlying mechanism. Experimental Approach Bile duct ligation and thioacetamide gavage were used to model liver fibrosis in C57BL/6J mice. Western blotting, immunolabelling and qPCR were employed for protein and mRNA expression. Liver injury/fibrosis were assessed using serum alanine transaminase and aspartate transaminase assays, haematoxylin–eosin, Masson and Sirius red staining. Adenoviruses were used to overexpress TRPC6 and CREB1 Y134F . ChIP and dual‐luciferase reporter assays were performed to test the direct inhibition of Acta2 transcription by CREB. Key Results TRPC6 protein levels were decreased in fibrotic liver tissues from both patients and mice, with the decrease being more robust in fibrotic areas. In hepatic stellate cells (HSCs), TRPC6 ablation aggravated liver injury and fibrosis, which was alleviated by overexpressing TRPC6. In primary cultured HSCs, deletion of TRPC6 exacerbated self‐activation of HSCs, which was reversed by restoration of TRPC6 expression. Mechanistically, TRPC6 suppressed HSC activation through CaMK4‐mediated CREB phosphorylation. CREB directly interacted with the promoter region of Acta2 to inhibit its transcription. Expression of a constitutively active form of CREB1 (CREB1 Y134F ) in HSCs attenuated BDL‐induced liver injury/fibrosis in TRPC6 knockout mice. Conclusion and Implications Deficiency of TRPC6 aggravates liver injury/fibrosis through augmentation of HSC activation. Increasing TRPC6 expression/function would be therapeutically beneficial for fibrotic liver diseases. LINKED ARTICLES This article is part of a themed issue Drugs and Drug Targets in Metabolic and Chronic Inflammatory Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.20/issuetoc

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisTRPC6 Cation ChannelCalcium-Calmodulin-Dependent Protein Kinase Type 4Cyclic AMP Response Element-Binding ProteinHepatic Stellate CellsSignal TransductionMolecular Targeted TherapyMice, Inbred C57BLHumansMaleAnimalsMiceGene ExpressionGene Expression Regulation

Stichwörter der Autor:innen

CREBCaMK4TRPC6hepatic stellate cellsliver fibrosis

Substanzen

TRPC6 Cation ChannelTrpc6 protein, mouseCalcium-Calmodulin-Dependent Protein Kinase Type 4Cyclic AMP Response Element-Binding ProteinCamk4 protein, mouseCreb1 protein, mouse

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines and Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Department of Gastroenterology, Zhongda Hospital, Nanjing, China.
  • Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
  • Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Yantai University, Yantai, China.
  • Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA.

ORCID-Profile: Michael X Zhu, Zhengyu Cao

Förderung

  • National Natural Science Foundation of China
  • 'Double First-Class' University Project
  • Taishan Scholar Foundation of Shandong Province
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Jiang, S., Wang, Y., Ren, Y., Tang, Q., Xue, C., Wang, Z., Zhang, Q., Hu, Y., Wang, H., Zhao, F., Zhu, M. X., & Cao, Z. (2025). TRPC6 suppresses liver fibrosis by inhibiting hepatic stellate cell activation via CaMK4‐CREB pathway. British Journal of Pharmacology, 182(20), 5004-5022. https://doi.org/10.1111/bph.17431

Vancouver

Jiang S, Wang Y, Ren Y, Tang Q, Xue C, Wang Z, et al. TRPC6 suppresses liver fibrosis by inhibiting hepatic stellate cell activation via CaMK4‐CREB pathway. British Journal of Pharmacology. 2025;182(20):5004-5022. doi:10.1111/bph.17431

BibTeX
@article{Jiang2025,
  author = {Jiang, Shan and Wang, Yujing and Ren, Younan and Tang, Qinglian and Xue, Chu and Wang, Zhi and Zhang, Qi and Hu, Yixin and Wang, Hongbo and Zhao, Fang and Zhu, Michael X and Cao, Zhengyu},
  title = {TRPC6 suppresses liver fibrosis by inhibiting hepatic stellate cell activation via CaMK4‐CREB pathway},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {20},
  pages = {5004--5022},
  doi = {10.1111/bph.17431}
}
Kostenlos starten →